Review of 30 Studies Finds GLP-1 Drugs May Cut Alzheimer's Plaques and Tangles
Updated
Updated · PsyPost · Aug 2
Review of 30 Studies Finds GLP-1 Drugs May Cut Alzheimer's Plaques and Tangles
2 articles · Updated · PsyPost · Aug 2
Summary
A systematic review of 30 preclinical studies and two small clinical trials found GLP-1 receptor agonists often reduced amyloid-beta plaques and tau tangles in lab and animal models of Alzheimer's disease.
Liraglutide showed the strongest preclinical signal: 13 of 15 studies reported lower amyloid-beta, and all 12 that measured tau found reductions, with dulaglutide and semaglutide also showing benefits in several animal tests.
Human evidence remained limited and inconclusive. In 38 Alzheimer's patients, liraglutide did not significantly cut amyloid-beta or improve cognition over 26 weeks, though it preserved brain glucose use; a 21-patient Exenatide trial also found no clear biomarker shift.
The review said the drugs may work through insulin signaling, lower inflammation or better cardiovascular health, but larger early-stage human trials are needed to test whether they can prevent dementia rather than treat established disease.